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Monitoring of single cell signal transduction in leukemic cellularsubsets has been proposed to provide deeper understandingof disease biology and prognosis, but has so far not been test-
ed in a clinical trial of targeted therapy. We developed a complete mass
cytometry analysis pipeline for characterization of intracellular signal
transduction patterns in the major leukocyte subsets of chronic phase
chronic myeloid leukemia. Changes in phosphorylated Bcr-Abl1 and
the signaling pathways involved were readily identifiable in peripheral
blood single cells already within three hours of the patient receiving
oral nilotinib. The signal transduction profiles of healthy donors were
clearly distinct from those of the patients at diagnosis. Furthermore,
using principal component analysis, we could show that phosphorylat-
ed transcription factors STAT3 (Y705) and CREB (S133) within seven
days reflected BCR-ABL1IS at three and six months. Analyses of periph-
eral blood cells longitudinally collected from patients in the ENEST1st
clinical trial showed that single cell mass cytometry appears to be  high-
ly suitable for future investigations addressing tyrosine kinase inhibitor
dosing and effect. (clinicaltrials.gov identifier: 01061177) 
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ABSTRACT
Introduction
Chronic myeloid leukemia (CML) is a hematologic stem
cell disorder driven by transcription of the fusion protein
Bcr-Abl1, a constitutively active tyrosine kinase.1 The
deregulated kinase activity is sufficient to maintain the
CML phenotype2,3 and leads to activation of several path-
ways, including JAK/STAT,4 PI3K/Akt5 and Ras/MAPK.6
Accordingly, specific tyrosine kinase inhibitors (TKIs) tar-
geting Bcr-Abl1 have revolutionized CML treatment. The
majority of patients display excellent cytogenetic and
molecular responses and remain free of disease progres-
sion.7-9 However, for many CML patients, a cure will prob-
ably not be achieved by TKIs alone because of the persist-
ence of leukemic stem cells that may cause relapse.10,11
Furthermore, a significant number of patients are switched
from one TKI to another because of insufficient efficacy or
adverse effects.12 Early identification of suboptimal
responders to TKI could facilitate optimal dosing and
choice of TKI thereby limiting adverse events and securing
optimal molecular responses.13 This could be accom-
plished by the direct assessment of Bcr-Abl1 kinase activ-
ity in the leukemic cells early after start of TKI therapy. 
Pharmacodynamic analysis of TKI effect on Bcr-Abl1
tyrosine kinase activity and subsequent downstream sig-
nal transduction in CML patients has been technically
challenging and thus rarely exploited in clinical trials.14,15
However, recent advances in single cell analysis of intra-
cellular signal transduction show promise both in diagnos-
tics and in therapeutic leukemia monitoring.16-18
Cytometry by Time of Flight (CyTOF) allows single cell
characterization of immunophenotypes and intracellular
signaling status in healthy individuals19,20 and patients with
hematologic malignancies.21 The technique enables meas-
urement of more than 40 parameters per cell, thereby dra-
matically increasing the dimensionality of acquired data
compared to conventional flow cytometry. This is
achieved by exploiting the resolution of mass spectrome-
try and stable rare-earth isotope-conjugated antibodies to
perform highly multiplexed assays on single cells. This has
permitted the  dynamic signal transduction events within
the hematologic hierarchy in acute myeloid leukemia to
be evaluated.22-24 
A panel of antibodies targeting more than 30 cell-surface
and intracellular phospho-specific epitopes covering the
major signaling molecules in Bcr-Abl1 oncogenic signaling
(pBCR Y177, pAbl Y245, pCRKL Y207, pSTAT1 Y701,
pSTAT3 Y705, pSTAT5 Y694, pCREB S133, pERK 1/2
T202/Y204, pS6 ribosomal protein S235/36 and S240/44)
were developed. By analyzing longitudinally collected
samples we show that both TKI-mediated changes in sig-
nal transduction and immunophenotypes is measurable,
and propose that a 1-tube-based analysis by mass cytom-
etry is a feasible biomarker strategy in clinical trials of
leukemia. 
Methods
Patients
Patients were eligible for the present study if they were enrolled
in the international phase IIIb ENEST1st study.25 Patients were
enrolled when they had newly diagnosed chronic phase CML,
were 18 years of age or older, and had a World Health
Organization (WHO) performance status no higher than  2. The
demographic and clinical parameters of all patients included in this
study (n=17) are shown in  Online Supplementary Tables S1 and S2.
Treatment consisted of nilotinib 300 mg BID. A peripheral blood
(PB) sample was collected before the first nilotinib dose, and three
hours, seven days and 28 days after the start of treatment. The
study was performed in accordance with the Declaration of
Helsinki, and all patients provided written informed consent. The
study was approved by the local institutional review boards of all
participating centers and is registered at clinicaltrials.gov identifier:
01061177. PB and bone marrow (BM) were collected from healthy
individuals after  written informed consent (University of Bergen,
Norway, local ethical committee approval 2012/1045).
Materials 
The primary material was fixed and erythrocytes lysed by
Lyse/Fix buffer (BD Phosflow) in local hospital laboratories and
immediately frozen in saline for long-term storage and shipping at
-80°C. The longitudinal PB samples from each patient (before first
dose of nilotinib, and after 3 hours, 7 days, and 28 days) were 
barcoded for identification, pooled and stained with the antibody
panels (Online Supplementary Table S3) according to the manufac-
turer's recommendation (MaxPar Phospho-Protein Staining
Protocol). In the preliminary dataset #1, a protocol for barcoding
was adapted from Zunder et al.26 (Online Supplementary Figure S1)
and barcoded reagents were a kind gift from Prof. Bernd
Bodenmiller, University of Zurich, Switzerland. The acquisition of
samples was performed on the CyTOF2 mass cytometer
(Fluidigm) at the Mass Cytometry Facility, University of Zurich,
Switzerland. In dataset #2, a commercially available barcoding kit
was used (Fluidigm). Acquisition of this dataset was performed
using the Helios mass cytometer (Fluidigm) at the Flow
Cytometry Core Facility, University of Bergen, Norway. 
Statistical analysis 
Friedman non-parametric test with Dunn’s multiple comparison
was used to find statistically significant changes in phosphoryla-
tion of intracellular targets (before, and after 3 hours and 7 days of
treatment). Wilcoxon matched-pairs signed rank test was used to
identify statistically significant changes in cell abundances before
and after initiation of nilotinib therapy. Prism software (GraphPad
Software Inc.) was used to calculate P-values and plot the graphs.
P≤0.05 was considered statistically significant.
Results
The immunophenotype and signal transduction in
CD34+cells of CML patients 
It has been proposed that both number of hematopoiet-
ic stem and progenitor cells (CD34+CD38low and
CD34+CD38high, respectively), and their signaling response
patterns to TKIs are important for response prediction in
CML.27 Therefore, we performed an initial analysis of the
PB CD34+ compartment before and after receiving the first
dose (3 hours and 7 days) of nilotinib in 17 patients
enrolled in the ENEST1st study. The 3 samples from each
patient were barcoded, pooled and stained with a validat-
ed panel of antibodies (Online Supplementary Figures S2 and
S3). The high dimensional single-cell data for each patient
were clustered using the SPADE algorithm,28 where manu-
al annotation identified several major hematologic cell
subsets, including the CD34+ cells. This population was
further gated manually into CD34+CD38low and
CD34+CD38high cells. Due to inter-patient variation in
CD38 expression range, the gating was tailored to each
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longitudinal patient sample set. Only patients for whom a
minimum of 100 cells could be identified as
CD34+CD38low and CD34+CD38high for all samples were
included in the final analysis (n=10). To characterize the
debulking of the tumor load at the single cell level and
over time, all CD34+ cells were analyzed using viSNE algo-
rithm.21 This allowed single cells from different samples to
be graphed in a unifying 2-dimensional plot, where its
(x,y) position contains information about cell surface
marker expression (see Figure 1A for 2 representative
patients' sample sets). CD34+CD38low cells resided in the
lower part of the viSNE plot, while CD34+CD38high cells
resided in the middle/top right. It has been suggested that
CD25 can be used to identify leukemic stem cells in
CML.29 In this pool of CD34+ cells collected from PB,
CD34+CD25+ cells are strongly aggregated towards the
very bottom of the viSNE plot, in the CD34+CD38low
region. During seven days of  TKI treatment, we saw a sta-
tistically significant (P≤0.01) depletion of CD34+ cells from
PB leukocytes (Figure 1B). Furthermore, after gating of
CD34+CD25+ double positive cells, we saw a statistically
significant depletion of CD34+CD25+ cells compared to
CD34+ cells at seven days of therapy  (Figure 1C). The 85th
percentile metal intensity of pAbl Y245, pCRKL Y207,
pSTAT3 Y705 and pSTAT5 Y694 was calculated for the
manually gated CD34+CD38low and CD34+CD38high single
cell populations. Comparing the changes of phosphoryla-
tion level across patients over time, we found a statistical-
ly significant increase in pSTAT3 Y705 in the
CD34+CD38high population (P≤0.05) between samples col-
lected before and after seven days of TKI therapy (Figure
1D). Based on these observations in the CML progenitor
compartment, we decided to examine more highly differ-
entiated CML cells based on a more extensive panel of
antibodies characterizing the myeloid and lymphoid 
lineages  in greater detail (Online Supplementary Figures S4
and S5)
Mass cytometry identified hematologic remission in
clinical trial samples
To validate our methodological approach, we analyzed
a second cohort of patients (n=8) enrolled in the ENEST1st
clinical trial. From each patient, 3 longitudinally collected
samples (before, and after 3 hours and day 7 of TKI treat-
Single cell profiling of CML by mass cytometry
haematologica | 2017; 102(8) 1363
Figure 1. Nilotinib dosing altered signal transduction of the CD34+ cell population in chronic phase chronic myeloid leukemia (CML) patients analyzed by mass
cytometry. Patient peripheral blood (PB) was collected at trial inclusion (t=0; before dosing), and after three hours (t=3h) and at day 7 (t=7d) of nilotinib (300 mg
BID). (A) The CD34+ subset identified by the SPADE algorithm was further analyzed by the viSNE algorithm.21 The CD34+ cells from 2 representative patients at the
three time points are shown. For each patient, the range of expression of each cell surface marker (CD34, CD38 and CD25) is color-coded from minimum to maxi-
mum expression of the three longitudinal samples. (B) The ratio of CD34+ cells and the total PB counts was calculated for all patients (n=10) in all three longitudinal
samples. We found a statistically significant decrease of CD34+ cells in the PB between t=0 and day 7, and between after three hours and day 7 (Friedman non-para-
metric with Dunn’s multiple comparison; **P≤0.01). (C) For all patients, CD34+CD25+ cells were identified on the viSNE plots (see gating scheme). The ratio between
CD34+CD25+ and all CD34+ cells was calculated showing a statistically significant decrease in CD34+CD25+ cells between diagnosis and day 7, and between after
three hours and day 7 (Friedman non-parametric with Dunn’s multiple comparison; **P≤0.01). (D) Intracellular signaling transduction targets of Bcr-Abl1. The 85th
percentile metal intensities of pAbl Y245, pCRKL Y207, pSTAT3 Y705, pSTAT5 Y694 and pCREB S133 were calculated and data of the patient cohort (n=10) for the
CD34+CD38low and CD34+CD38high populations box plotted as a function of time. We observed a statistically significant change of pSTAT3 Y705 in the CD34+CD38high
population (Friedman non-parametric with Dunn’s multiple comparison, *P≤0.05) between samples collected at diagnosis and day 7. 
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ment) were barcoded, along with 4 healthy PB and 4
healthy BM samples, using the commercially available 20-
plex metal barcoding kit (Fluidigm). Each longitudinal set
of 3 samples from a patient, and healthy PB and BM, was
analyzed using the SPADE clustering algorithm,28 and the
major leukocyte subsets were manually identified and
annotated (Figure 2A). The relative abundance of a selec-
tion of cellular subsets quantified in longitudinal samples
collected before and after seven days of TKI therapy is
shown in Figure 2B and C.  The abundance of the corre-
sponding healthy cell subset is shown in a lighter shade,
identified either from the healthy PB or BM samples  (n=4
each). Similar to previous results (Online Supplementary
Figure S3), already at day 7 of TKI therapy we observed a
statistically significant change in the relative abundance of
several cellular subsets. We measured a statistically signif-
icant reduction of myelocytes and progenitor cells
(CD34+CD38low), and an expansion of mature neutrophils,
CD8+ T cells, and activated T cells, (Wilcoxon matched
pairs signed rank test P>0.05 for all). 
The direct measurement of phosphorylated Bcr-Abl1 in
single cells from patients treated with nilotinib 
The phosphorylation level of several key signaling mol-
ecules in the Bcr-Abl1 signal transduction network was
characterized in each patient, as a function of time and
nilotinib treatment (before, and after 3 hours and 7 days of
TKI therapy; n=8), and in the healthy PB and BM (n=4
each) (Figure 3A). In general, these data support our initial
findings (Online Supplementary Figure 3C), reproducing the
clearly distinct signaling status observed in healthy PB and
CML at diagnosis, including the attenuated level of
pSTAT3 Y694 phosphorylation in the CML neutrophils. In
the larger patient cohort (n=8), we are able to measure a
statistically significant decrease in pCRKL Y207 as a func-
tion of Bcr-Abl1 inhibition in the basophils (between
before and after 7 days on TKI; P≤0.05), and an increase in
pSTAT5 Y694 in the CD4 T helper cells (between diagno-
sis and after 3 hours of TKI; P≤0.01). We also measured a
clear trend of pAbl Y245 downregulation in the
CD34+CD38– population as a function of TKI-therapy
(simple Wilcoxon test after 7 days of TKI P=0.0313). The
seemingly ubiquitous regulation of pCREB S133, initial
decrease and subsequent increase, reached statistical sig-
nificance in the neutrophils (between before and after 7
days, and between diagnosis and after 3 hours of TKI;
P≤0.05 for both) but was observed in several cellular sub-
sets. In the hematopoietic stem and progenitor compart-
S.-E. Gullaksen et al.
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Figure 2. High-resolution single cell immune profiles of healthy and patient leukocytes. Longitudinally collected samples (before, after 3 hours and day 7 on nilotinib)
from 8 patients in the ENEST1st trial, together with 4 healthy peripheral blood (PB) and bone marrow (BM) samples, were barcoded using the 20-plex metal barcoding
kit (Fluidigm). (A) Data from the longitudinal samples from each patient, and the  4 healthy PB and BM samples, were pooled and clustered using the SPADE algo-
rithm28 and manually annotated to identify cellular subsets. The SPADE tree analysis of patient 4702_0004 is shown. The size of each node represents the number
of cells clustered and the expression of pSTAT3 Y705 is color-coded. The red bubble highlights the mature neutrophil population. (B and C) The relative abundance
of the major PB populations identified in samples collected at diagnosis and after seven days of tyrosine kinase inhibitor (TKI) therapy is shown for the patient cohort
(n=8, error bars showing standard error of mean, SEM), with the appropriate subpopulation in the healthy samples shown in a lighter shade. CD34+ cells could only
be identified in 7 out of 8 patients. Wilcoxon matched-pairs rank test was used to identify statistically significant changes from before and after seven days of TKI
therapy, where P≤0.05 was considered statistically significant.  
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ment (Figure 3B), we reproduced a statistically significant
increase in pSTAT3 Y694 (between after 3 hours of TKI
and after 7 days of TKI; P≤0.05) similar to what can be
seen in the CD34+CD38high progenitor cell population
(Figure 1D). 
TKI-mediated changes in single cell signal 
transduction reflects BCR-ABL1IS at 3 and 6 months
Finally, we examined whether the observed 
TKI-induced changes in signal transduction networks could
provide prognostic  information. We split the patients
according to their BCR-ABL1IS at three and six months into
two response groups (Figure 3C, low in green and high in
red). The arcsinh fold change of each signal transduction
epitope (n=10) between diagnosis and after seven days of
TKI treatment was calculated for the neutrophils and mye-
locytes for all patients (n=8). We performed an unsuper-
vised multivariate principle component analysis (PCA) of
the fold change data using Unscrambler X (CAMO
Software), and then manually overlaid the response group
affiliation (Figure 3D). The PCA analysis revealed underly-
ing differences in signaling status between the response
groups, driven mainly by the rates of downregulation of
pCREB S133 and upregulation of  pSTAT3 Y705.
Discussion
Mass cytometry enabled the measurement of more than
30 intracellular and cell surface markers on each single cell,
with an additional six channels reserved for metal barcod-
ing for sample multiplexing.30 The convenient single tube
labeling of multiplexed samples combined with semi-
automatic analysis makes the technique highly efficient.
We were able to recapitulate the expected hematologic
response, and  could also demonstrate the debulking of
leukemic CD34+ cells in the PB by immunophenotyping as
early as one week after start of therapy. Importantly, by
simultaneously probing key intracellular phosphorylation
targets of the Bcr-Abl1 signaling network,2,3 we monitored
changes in signal transduction of individual cell types for
each patient undergoing TKI therapy. Unsupervised prin-
ciple component analysis of these early changes in signal
transduction allowed patients to be identified according to
their BCR-ABL1IS, indicating a possible future prognostic
impact of this approach.
The proportion of leukemic stem cells (as determined by
FISH) in the BM of chronic phase CML have been shown
to have a prognostic significance.26 In the PB of our
patients, we were able to monitor the therapy-dependent
debulking of CD34+ cells (Figure 1B), and both
CD34+CD38low and CD34+CD38high cells (data not shown), at
day 7 of therapy. Interestingly, at day 7 we saw a statisti-
cally significant depletion of CD34+CD25+, a putative
CML stem cell subset27 compared to all CD34+ cells (Figure
1C). This could indicate an increased sensitivity to TKI or
alternatively an increased bone marrow homing of this
cell subset.29 Early relative increase of lymphocytes in the
PB of CML patients treated with TKI has also previously
been shown to have prognostic importance.31 Our
immune profiling of patient leukocytes allowed a high-
resolution picture of PB subpopulations, enabling the
Single cell profiling of CML by mass cytometry
haematologica | 2017; 102(8) 1365
Figure 3. Single cell signaling profiles correlate to BCR-ABL1IS molecular response. The phosphorylation level (75th percentile of metal intensity) of the intracellular
Bcr-Abl1 signaling network (n=10) was measured in the longitudinal samples (before, after 3 hours and after 7 days of nilotinib) in the patient cohort (n=8), toge-
ther with 4 healthy peripheral blood (PB)  and bone marrow (BM) samples. (A) We observed distinctly different states of signal transduction in the patient samples
compared to the healthy controls. (B) The Lin-CD34+CD38low and Lin–CD34+CD38high cell populations were manually gated from the CD34+ population identified by
SPADE, and the intracellular signal transduction measured. CD34+ cells could only be identified in 7 out of 8 patients. The same strategy was followed for healthy
CD34+ cells. For both (A and B) statistical significance was determined using Friedman non-parametric with Dunn’s multiple comparison test, where P≤0.05 was con-
sidered statistically significant (*P≤0.05, **P≤0.01). (C) The BCR-ABL1IS of each patient during tyrosine kinase inhibitor (TKI) therapy. The patient cohort was divided
into two groups based on the BCR-ABL1IS at three and six months (red and green). (D) An unsupervised PCA analysis of the signal transduction arcsinh fold change
compared samples before and after seven  days of nilotinib treatment in the mature neutrophils (Neutro) and myelocytes (Myelo) was performed using Unscramble
software (CAMO Software). The categorical color-coding from (C) was superimposed on the resulting PCA plot, and the dashed line was drawn manually.
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simultaneous monitoring of the size of all major
hematopoietic lineages. Here, the analysis of healthy PB
and BM side-by-side with primary material clearly delin-
eates cell populations dominating in CML compared to
healthy individuals (Figure 2). Interestingly, we were able
to measure statistically significant changes in abundances
for several cellular subpopulations, including an increase in
PB CD8+ cytotoxic T cells already after seven days of TKI
therapy. 
We believe that a particular strength of our single cell
analysis is the direct monitoring of nilotinib-induced
changes in signal transduction. This includes the primary
target kinase for nilotinib, Abl1, as well as its immediate
substrates like pCRKL Y20732 and pivotal Abl1-affected
signal transduction pathways in myeloid neoplasias, e.g.
the STAT3/5 pathway.16,17,33
We established a metal barcoded pool of stimulated cell
lines for functional validation of our panel of phospho-spe-
cific antibodies (Online Supplementary Figure S5). Indeed, we
could measure a statistically significant reduction of pCRKL
Y207 in the basophils as a function of nilotinib therapy in
our patents (n=8) (Figure 3A). Compared to healthy con-
trols, we could measure a clearly attenuated pSTAT3 Y705
in mature neutrophils (Figure 3A and Online Supplementary
Figure S3C) and in the CD34+CD38high progenitor compart-
ment (Figures 1C and 3C) collected before treatment initia-
tion, which subsequently increased during TKI treatment.
A similar increase in pSTAT3 Y705 has previously been
reported in both mature neutrophils and CD34+ cells.34,35 In
BCR-ABL1 oncogene-addicted CML cells, it has been
shown that growth factor receptor signaling is dampened
through MEK/ERK-dependent negative feedback of the
BCR-ABL1 signal.36 This may explain the attenuated basal
level of phosphorylation of pSTAT3. Finally, we observe a
decrease of pCREB S133 as early as three hours after first
TKI dosing in several cellular subsets followed by an
increase after seven days. Interestingly, we see that, com-
pared to non-CML cell lines, K562 cells express high levels
of pCREB S133 at baseline that was reduced by TKI treat-
ment (Online Supplementary Figure S5C). Using a principle
component analysis to analyze changes in signal transduc-
tion between diagnosis and after seven days of TKI treat-
ment, we could discriminate patient groups according to
their BCR-ABL1IS at three and six months (Figure 3D). The
PCA analysis was driven mainly by mutual regulation of
pCREB S133 and pSTAT3 Y705, and underscores a potential
prognostic application for this assay. 
In summary, here we  demonstrate the first human
study of signal transduction in cancer cells from nilotinib-
treated CML patients in a prospective clinical trial, demon-
strating significant phosphorylation of CREB and STAT3
in chronic phase CML patients early after start on therapy.
We propose that mass cytometry, enabling simultaneous
measurement of more than 30 parameters on single cells,
may provide  a highly detailed characterization of CML
that allows comprehensive 1-tube-based monitoring of
the disease in patients during TKI therapy. The method
outlined here will allow early changes in individual
patient’s  immunophenotype and signal transduction as a
function of TKI therapy to be monitored in clinical trials.
Furthermore, this approach may shed light on the relation
between the kinetics of TKI-modulated signal transduc-
tion and clinical response. We anticipate this technology
to have high clinical impact by providing cancer cell signal
transduction profiles in patients close to real time after
start of TKI therapy. Additional work on standardization
of antibody panels is a prerequisite if mass cytometry is to
be established as a future tool to guide signal transduction-
targeted therapy.
Acknowledgments
The authors would like to thank personnel at the following
ENEST1st study centers for participating in this sub-study: VU
University Medical Center, Amsterdam, the Netherlands;
Cliniques Universitaires St Luc, Brussels, Belgium; University of
Helsinki and Comprehensive Cancer Center, Helsinki University
Hospital, Finland; Cliniques Universitaires St Luc, Brussels,
Belgium; University Hospital Bonn (UKB), Bonn, Germany;
Wels-Grieskirchen Hospital, Wels, Austria; Hospital Feldkirch,
Austria; University Hospital, Aarhus, Denmark; Oslo University
Hospital, Oslo, Norway; St Olavs Hospital Trondheim,
Norway; Stavanger University Hospital, Norway; Haukeland
University Hospital, Bergen; Norway; MTZ Clinical Research,
Warsaw, Poland; University Hospital Leuven, Belgium;
University Hospital Center Rebro, Zagreb, Croatia; Karolinska
University Hospital, Stockholm, Sweden; Medical University of
Gdańsk, Poland; University Hospital Sofia, Bulgaria.  
Funding
This study was supported by The Research Council of Norway
(Petromaks program grant #220759), Helse Vest health trust
and the Norwegian Cancer Society with Solveig & Ole Lunds
Legacy. Novartis is acknowledged for financially supporting data
and sample collection for this sub-study.
S.-E. Gullaksen et al.
1366 haematologica | 2017; 102(8)
References
1. Nowell PC, Hungerford DA. A minute
chromosome in human granulocytic
leukemia. Science. 1960;32:1497-1501.
2. Deininger MW, Goldman JM, Melo JV. The
molecular biology of chronic myeloid
leukemia. Blood. 2000;96(10):3343-3356.
3. Cilloni D, Saglio G. Molecular pathways:
BCR-ABL. Clin Cancer Res. 2012;18(4):
930-937.
4. Chai SK, Nichols GL, Rothman P.
Constitutive activation of JAKs and STATs
in BCR-Abl-expressing cell lines and
peripheral blood cells derived from
leukemic patients. J Immunol. 1997;159
(10):4720-4728.
5. Ly C, Arechiga AF, Melo JV, Walsh CM,
Ong ST. Bcr-Abl kinase modulates the
translation regulators ribosomal protein S6
and 4E-BP1 in chronic myelogenous
leukemia cells via the mammalian target of
rapamycin. Cancer Res. 2003;63(18):5716-
5722.
6. Cortez D, Reuther G, Pendergast AM. The
Bcr-Abl tyrosine kinase activates mitogenic
signaling pathways and stimulates G1-to-S
phase transition in hematopoietic cells.
Oncogene. 1997;15(19):2333-2342.
7. Hughes TP, Hochhaus A, Branford S, et al.
Long-term prognostic significance of early
molecular response to imatinib in newly
diagnosed chronic myeloid leukemia: an
analysis from the International
Randomized Study of Interferon and
STI571 (IRIS). Blood. 2010;116(19):3758-
3765.
8. Rosti G, Palandri F, Castagnetti F, et al.
Nilotinib for the frontline treatment of
Ph(+) chronic myeloid leukemia. Blood.
2009;114(24):4933-4938.
9. Cortes JE, Jones D, O'Brien S, et al. Results
of dasatinib therapy in patients with early
chronic-phase chronic myeloid leukemia. J
Clin Oncol. 2010;28(3):398-404.
10. Graham SM, Jørgensen HG, Allan E, et al.
Primitive, quiescent, Philadelphia-positive
stem cells from patients with chronic
myeloid leukemia are insensitive to STI571
in vitro. Blood. 2002;99(1):319-325.
11. Jorgensen HG, Allan EK, Jordanides NE,
Mountford JC, Holyoake TL. Nilotinib
exerts equipotent antiproliferative effects
to imatinib and does not induce apoptosis
in CD34+ CML cells. Blood. 2007;
109(9):4016-4019.
12. Hochhaus A, O'Brien SG, Guilhot F, et al.
Six-year follow-up of patients receiving
imatinib for the first-line treatment of
chronic myeloid leukemia. Leukemia.
2009;23(6):1054-1061.
13. Quintás-Cardama A, Kantarjian H, Jones D,
et al. Delayed achievement of cytogenetic
and molecular response is associated with
increased risk of progression among
patients with chronic myeloid leukemia in
early chronic phase receiving high-dose or
standard-dose imatinib therapy. Blood.
2009;113(25):6315-6321.
14. Iliuk AB, Tao WA. Is phosphoproteomics
ready for clinical research? Clin Chim Acta.
2013;420:23-27.
15. Baca Q, Cosma A, Nolan G, Gaudilliere B.
The road ahead: Implementing mass
cytometry in clinical studies, one cell at a
time. Cytometry B Clin Cytom. 2017;
92(1):10-11.
16. Skavland J, Jørgensen KM, Hadziavdic K, et
al. Specific cellular signal-transduction
responses to in vivo combination therapy
with ATRA, valproic acid and theophylline
in acute myeloid leukemia. Blood Cancer J.
2011;1(2):e4.
17. Kotecha N, Flores NJ, Irish JM, et al. Single-
cell profiling identifies aberrant STAT5 acti-
vation in myeloid malignancies with specif-
ic clinical and biologic correlates. Cancer
Cell. 2008;14(4):335-343.
18. Jalkanen SE, Lahesmaa-Korpinen AM,
Heckman CA, et al. Phosphoprotein profil-
ing predicts response to tyrosine kinase
inhibitor therapy in chronic myeloid
leukemia patients. Exp Hematol.
2012;40(9):705-714.e03.
19. Bendall SC, Simonds EF, Qiu P, et al. Single-
cell mass cytometry of differential immune
and drug responses across a human
hematopoietic continuum. Science. 2011;
332(6030):687-696.
20. Bodenmiller B, Zunder ER, Finck R, et al.
Multiplexed mass cytometry profiling of
cellular states perturbed by small-molecule
regulators. Nat Biotechnol. 2012;30(9):858-
867.
21. Amir el-AD, Davis KL, Tadmor MD, et al.
viSNE enables visualization of high dimen-
sional single-cell data and reveals pheno-
typic heterogeneity of leukemia. Nat
Biotechnol. 2013;31(6):545-552.
22. Levine JH, Simonds EF, Bendall SC, et al.
Data-Driven Phenotypic Dissection of
AML Reveals Progenitor-like Cells that
Correlate with Prognosis. Cell.
2015;162(1):184-197.
23. Behbehani GK, Samusik N, Bjornson ZB,
Fantl WJ, Medeiros BC, Nolan GP. Mass
Cytometric Functional Profiling of Acute
Myeloid Leukemia Defines Cell-Cycle and
Immunophenotypic Properties That
Correlate with Known Responses to
Therapy. Cancer Discov. 2015;5(9):988-
1003.
24. Han L, Qiu P, Zeng Z, et al. Single-cell mass
cytometry reveals intracellular
survival/proliferative signaling in FLT3-
ITD-mutated AML stem/progenitor cells.
Cytometry A. 2015;87(4):346-356.
25. Hochhaus A, Rosti G, Cross NC, et al.
Frontline nilotinib in patients with chronic
myeloid leukemia in chronic phase: results
from the European ENEST1st study.
Leukemia. 2016;30(1):57-64.
26. Zunder ER, Finck R, Behbehani GK, et al.
Palladium-based mass tag cell barcoding
with a doublet-filtering scheme and single-
cell deconvolution algorithm. Nat Protoc.
2015;10(2):316-333.
27. Mustjoki S, Richter J, Barbany G, et al.
Impact of malignant stem cell burden on
therapy outcome in newly diagnosed
chronic myeloid leukemia patients.
Leukemia. 2013;27(7):1520-1526.
28. Qiu P, Simonds EF, Bendall SC, et al.
Extracting a cellular hierarchy from high-
dimensional cytometry data with SPADE.
Nat Biotechnol. 2011;29(10):886-891.
29. Kobayashi CI, Takubo K, Kobayashi H, et
al. The IL-2/CD25 axis maintains distinct
subsets of chronic myeloid leukemia-initi-
ating cells. Blood. 2014;123(16):2540-2549.
30. Gavasso S, Gullaksen SE, Skavland J,
Gjertsen BT. Single-cell proteomics:  poten-
tial implications for cancer diagnostics.
Expert Rev Mol Diagn.  2016;16(5):579-589.
31. Kumagai T, Matsuki E, Inokuchi K, et al.
Relative increase in lymphocytes from as
early as 1 month predicts improved
response to dasatinib in chronic-phase
chronic myelogenous leukemia. Int J
Hematol. 2014;99(1):41-52.
32. Nichols GL, Raines MA, Vera JC, Lacomis
L, Tempst P, Golde DW. Identification of
CRKL as the constitutively phosphorylated
39-kD tyrosine phosphoprotein in chronic
myelogenous leukemia cells. Blood. 1994;
84(9):2912-2918.
33. Irish JM, Hovland R, Krutzik PO, et al.
Single cell profiling of potentiated 
phospho-protein networks in cancer cells.
Cell. 2004;118(2):217-228.
34. Jalkanen SE, Vakkila J, Kreutzman A,
Nieminen JK, Porkka K, Mustjoki S. Poor
cytokine-induced phosphorylation in
chronic myeloid leukemia patients at diag-
nosis is effectively reversed by tyrosine
kinase inhibitor therapy. Exp Hematol.
2011;39(1):102-113.e1.
35. Eiring AM, Page BD, Kraft IL, et al.
Combined STAT3 and BCR-ABL1 inhibi-
tion induces synthetic lethality in therapy-
resistant chronic myeloid leukemia.
Leukemia. 2015;29(3):586-597.
36. Asmussen J, Lasater EA, Tajon C, et al.
MEK-dependent negative feedback under-
lies BCR-ABL-mediated oncogene addic-
tion. Cancer Discov. 2014;4(2):200-215.
Single cell profiling of CML by mass cytometry
haematologica | 2017; 102(8) 1367
